Dong-A ST’s licensing-out treatment is under new drug application in the U.S.

Cubist Pharmaceuticals, Inc., a new U.S. partner of Dong-A ST, said on Tuesday that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic tedizolid phosphate (TR-701).

Cubist added tedizolid phosphate to its pipeline through the recent acquisition of Trius Therapeutics

Dong-A ST and Trius Therapeutics e...